

Customer No. 26874

PATENT

Atty. Docket No. 0091830.0542088

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Walzer, Peter D. : Examiner: Unknown

Serial No. 10/595,999 : Group Art Unit: Unknown

Filed: 05/24/2006 : Atty. Ref.: 0091830.0542088

For: **BISBENZAMIDINES FOR THE TREATMENT OF PNEUMONIA**

AMENDMENT AND RESPONSE

MS RCE
COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action, dated September 17, 2007, please consider the following remarks.

Remarks begin on page 2 of this paper.

Remarks

The Notification to comply with requirements for patent applications containing nucleotide and/or amino acid sequence disclosures sent on September 17, 2007 indicates that the application clearly fails to comply with the requirements of 37 CFR 1.821-1.825, and that a copy of the “Sequence Listing” in computer readable form must be submitted as required by 37 CFR 1.821(e).

The application does not contain any sequence that falls under 37 CFR 1.821-1.825, and consequently there is no requirement to submit a copy of the “Sequence Listing” in computer readable form. If this assertion is incorrect, please specifically point out the location of the sequence in the application so that the application may be amended to comply with 37 CFR 1.821-1.825.

Respectfully Submitted,

/Scott R. Conley, Ph.D/

Scott R. Conley, Ph.D. (Reg. No. 57,289)
Frost Brown Todd LLC
2200 PNC Center
201 E. Fifth Street
Cincinnati, Ohio 45202-4182
513-651-6818 (direct)
513-651-6981 (fax)